Highlights Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
0.4083 ^USD	-2.34%		-1.73%	-0.46%

Jan. 13	Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities	RE
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI

Highlights

Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI
Dec. 05	Intensity Therapeutics Gets Extension to Regain Nasdaq Minimum Price Requirement	MT
Nov. 06	Intensity Therapeutics Q3 net loss narrows to $2.7 mln	RE
Nov. 06	Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal	CI
25-09-10	Intensity Therapeutics, Inc. Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update	CI
25-08-07	Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-04	Intensity Therapeutics raises $6.6 million from at the market offering (ATM) stock sales	RE
25-06-30	Intensity Therapeutics, Inc. Announces Int230-6 Achieves 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors	CI
25-06-11	Intensity Therapeutics Prices Public Offering Of 6,675,000 Shares At $0.30 Per Share	RE
25-06-11	Intensity Therapeutics Announces Proposed Public Offering Of Common Stock	RE
25-06-11	Intensity Therapeutics, Inc. Announces Patients Receiving Int230-6 Prior to the Start of Standard-Of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 Invincible-4 Study	CI
25-05-13	Intensity Therapeutics Q1 Basic EPS USD -0.22	RE
25-05-13	Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-06	Intensity Therapeutics, Inc. and the Swiss Group for Clinical Cancer Research Sakk Receive European Medicines Agency Authorization to Initiate Phase 2 Invincible-4 (Sakk/66/22) Study for Int230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France	CI
25-03-13	Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-12-13	Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares	MT
24-12-12	Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial	MT
24-12-12	Intensity Therapeutics, Inc. and the Swiss Group for Clinical Cancer Research Sakk Present Phase 2 Data in Presurgical Breast Cancer from the Completed Invincible-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, At the 2024 San Antonio Breast Cancer Symposium	CI
24-11-18	Intensity Therapeutics, Inc. Presents Int230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial	CI
24-11-13	Earnings Flash (INTS) INTENSITY THERAPEUTICS Reports Q3 Loss $-0.25	MT
24-11-13	Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-31	Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)	CI
24-08-08	Earnings Flash (INTS) INTENSITY THERAPEUTICS Posts Q2 Loss $-0.36	MT
24-08-08	Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Highlights

Filters